Leiden, The Netherlands, 22nd of August 2016 – The Modelling & Simulation community is poised to benefit from the first fully integrated open-source modelling environment, proudly released by the... Read more
The interoperability framework will produce a modular, functional implementation of the interoperability software platform. This platform will house a convertor toolbox that will permit conversion among the different languages i.e. the languages as originally used by the models as deposited in the model repository, the Model Description Language (MDL) and Model Mark-up Language (MML). The Application Programming Interface (API) will permit manipulation of the MML/MDL files and facilitates interaction with the model repository, existing software tools and newly developed tools. In addition, a workflow environment will be set up to permit end-to-end modelling and reporting. The environment will be tested via a demonstration project.
Main outcomes of WP2
Leiden, The Netherlands, 22nd of August 2016 – The Modelling & Simulation community is poised to benefit from the first fully integrated open-source modelling environment, proudly released by the... Read more
Location: GSK House, 980 Great West Rd, Brentford, London, Middlesex TW8 9GS Date: 17th March (from 12:00) – 18th March (until last man standing)https://goo.gl/maps/N3qqgsr9rkq Transport links from... Read more
MDL-IDE The Modelling Description Language (MDL) is a human writeable and human readable language to express the information required to describe pharmacometric models and the tasks that utilise... Read more
An initial prototype for the DDMoRe framework was demonstrated in December 2012 showing the end-to-end process of import, modification, execution and post-processing of NONMEM models. The... Read more
January 28 - 30, Denmark MML/Technical meeting has very kindly been sponsored by Novo Nordisk. The meeting co-locates two separate workshops focussing on the MML specification and the technical/... Read more
© 2012 - 2016 | DDMoRe, all rights reserved. 
Support was received from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115156, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution. The DDMoRe project is also financially supported by contributions from Academic and SME partners